Nanocarry Therapeutics

Cover Block

PUBLIC

Attribute	Value
Name	Nanocarry Therapeutics
Tagline	Developing a nanoparticle platform to deliver biologic drugs across the blood-brain barrier for neuro-oncology and CNS indications.
Headquarters	Weizmann Science Park, Israel
Founded	2021
Stage	Pre-Seed
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout

Links

PUBLIC

• Website: https://nanocarry.com/
• LinkedIn: https://il.linkedin.com/company/nanocarry-therapeutics

Executive Summary

PUBLIC

Nanocarry Therapeutics is a preclinical Israeli biotech developing a nanoparticle platform to deliver biologic drugs across the blood-brain barrier, a technical hurdle that has long limited treatment options for brain tumors and central nervous system diseases [LinkedIn, Unknown]. The company’s AxS platform, described as a “Plug and Play” system, uses a gold nanoparticle core engineered to bind therapeutic antibodies and exploit insulin pathways for transport, with preclinical data suggesting it can deliver up to 30 times more antibody to the brain than standard methods [Bar-Ilan University, Unknown]. Founded in 2021 as a spinout from Bar-Ilan University, the company’s initial focus is on brain metastases from HER2-positive breast cancer and non-small-cell lung cancer, aiming to turn previously inaccessible tumors into drug-accessible targets [Bar-Ilan University, Unknown]. The business model is B2B, with the implied path being partnership with larger pharmaceutical companies seeking brain-penetrant delivery for their biologic assets. Public data on funding is notably sparse, with no verifiable press releases detailing round amounts, dates, or lead investors, a point corroborated by Tracxn’s note that the company has not raised any funding rounds yet [Tracxn, Unknown]. Over the next 12 to 18 months, the critical watchpoints will be the announcement of a first institutional financing round, the progression of its lead candidate into formal IND-enabling studies, and the disclosure of any strategic pharma partnerships to validate the platform’s commercial potential.

Data Accuracy: YELLOW -- Core platform claims are well-sourced from university and company materials, but key financial and team details lack independent corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Biotech / Life Sciences
Technology Type	Deeptech
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout

Company Overview

PUBLIC

Nanocarry Therapeutics is an Israeli preclinical biotechnology company founded in 2021, operating from the Weizmann Science Park [LinkedIn]. The company was established to commercialize academic research focused on breaching the blood-brain barrier, specifically originating from Bar-Ilan University, which describes Nanocarry as "a biotech startup born at Bar-Ilan University" [Bar-Ilan University]. Its core mission, articulated from inception, is to develop a platform technology that makes brain tumors and central nervous system diseases accessible to biologic drugs, a class of therapeutics historically blocked by the brain's protective barrier.

Since its founding, the company's primary disclosed milestone is the development of its AxS nanoparticle platform to a preclinical stage. Research published by the affiliated university indicates preclinical studies demonstrating the platform's ability to deliver significantly higher concentrations of therapeutic antibodies to the brain compared to standard methods [Bar-Ilan University]. A subsequent signal of external validation came in 2022, when the company's brain-penetrating nanoplatform was selected for an unspecified program aimed at improving therapy delivery, as noted in a brief industry news item [FirstWord Pharma, 2022].

Operational details remain limited. The company maintains a small team, with public data suggesting a headcount between 2 and 20 employees [LinkedIn][Prospeo]. Senior leadership includes Michal Roytman, who is listed as Chief Business Officer [Synapse-Patsnap]. No founding team members are named in primary public sources, and the company's funding history is not publicly disclosed, with no verifiable press releases detailing seed or Series A rounds [Tracxn].

Data Accuracy: YELLOW -- Core founding details are confirmed by the company's LinkedIn and university sources, but key operational and financial milestones lack independent public corroboration.

Product and Technology

MIXED The core of Nanocarry's proposition is a nanoparticle delivery platform designed to solve a specific, long-standing biophysical problem: transporting large biologic drugs across the blood-brain barrier. The company's AxS platform uses a gold nanoparticle core engineered to bind a therapeutic antibody on one side and exploit the body's own insulin transport mechanism on the other, effectively hitching a ride across the barrier [Bar-Ilan University]. The company describes this as a "Plug and Play" system, suggesting the nanoparticle can be adapted to deliver a wide array of biologics beyond its initial targets [LinkedIn].

Preclinical data cited by the originating university indicates a significant performance edge. Studies show the AxS platform can deliver up to 30 times more therapeutic antibodies to the brain compared to standard methods [Bar-Ilan University]. This claimed efficacy underpins the company's lead programs, which target brain metastases from HER2-positive breast cancer (candidate AxS-007) and non-small-cell lung cancer [Bar-Ilan University] [LinkedIn]. The company's public pipeline page lists programs in neuro-oncology and CNS diseases, though it does not disclose specific development phases or timelines [Nanocarry].

While the platform's biologic-agnostic nature is a stated feature, there is no public detail on specific modifications required for different drug classes or on the scalability of the manufacturing process. The technology remains in the preclinical stage, with no announced clinical trial partners or regulatory filings. A brief external note indicates the platform was selected for an unspecified program aimed at improving brain delivery, which serves as a signal of external validation, though the selecting entity is not named [FirstWord Pharma].

Data Accuracy: GREEN -- Platform claims and preclinical data are confirmed by the originating university and company materials.

Market Research

PUBLIC

The core challenge Nanocarry aims to solve, delivering biologic drugs to the brain, has remained a stubborn bottleneck in neurology and oncology, creating a clear commercial gap for any platform that can reliably cross it.

Third-party market sizing specific to brain-penetrant biologic delivery platforms is not publicly available. However, the total addressable market for Nanocarry's initial focus can be inferred from the broader neuro-oncology and central nervous system (CNS) disease landscape. The global market for brain tumor treatments was valued at approximately $3.4 billion in 2022 and is projected to grow at a compound annual growth rate of 9.5% [Grand View Research, 2023]. More specifically, the market for brain metastasis treatments, which includes Nanocarry's lead programs for HER2+ breast cancer and NSCLC, represents a significant subset of this figure. The unmet need is pronounced; brain metastases occur in up to 30% of patients with solid tumors, and current systemic therapies often fail due to poor blood-brain barrier penetration [CNS Oncology, 2022].

Demand is driven by several converging tailwinds. The continued expansion of antibody-based therapeutics in oncology and neurology creates a growing pipeline of potent drugs that cannot reach their intracranial targets. Advances in cancer survival rates are paradoxically increasing the incidence of brain metastases as patients live longer with controlled systemic disease. Furthermore, regulatory agencies have shown a willingness to grant expedited pathways for novel drug delivery technologies that address serious unmet medical needs, as evidenced by recent breakthrough therapy designations for other CNS-targeting platforms [FDA, 2024].

Key adjacent markets that could expand the platform's utility include neurodegenerative diseases like Alzheimer's and Parkinson's, where biologic therapies (e.g., monoclonal antibodies targeting amyloid-beta or alpha-synuclein) are a major research focus but face the same delivery hurdle. The platform's "Plug and Play" claim suggests potential application in delivering gene therapies or other large-molecule modalities to the CNS, though this remains a longer-term technical and regulatory frontier. A primary macro risk is the capital-intensive and lengthy nature of CNS drug development, where clinical trial failures are common and regulatory scrutiny is high, potentially deterring partnership interest until robust human proof-of-concept data is generated.

Metric	Value
Global Brain Tumor Therapeutics (2022)	3.4 $B
Projected CAGR (2023-2030)	9.5 %

The projected market growth underscores the commercial urgency behind solving the blood-brain barrier problem, though Nanocarry's specific share of that market remains entirely dependent on preclinical and clinical validation.

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report; specific platform TAM is not confirmed.

Competitive Landscape

MIXED Nanocarry Therapeutics operates in a field defined by a fundamental scientific bottleneck, where competition is less about head-to-head product launches and more about distinct approaches to solving the same delivery problem.

The competitive landscape must be mapped through the broader technical and commercial approaches vying to treat central nervous system (CNS) malignancies.

• Large Pharma Internal Programs. Major oncology-focused pharmaceutical companies, such as Roche (Genentech) and AstraZeneca, maintain extensive R&D efforts to develop brain-penetrant versions of their antibody therapies, often through chemical modification (e.g., antibody-drug conjugate optimization) or screening for innate blood-brain barrier (BBB) penetration [FirstWord Pharma]. These efforts represent a substitute path to the same goal, leveraging vast internal resources and clinical development expertise but often remaining tied to specific asset pipelines rather than a platform.
• Specialized Biotech Platforms. A cohort of venture-backed biotechs is pursuing platform-based solutions. Companies like Denali Therapeutics (public, market cap ~$1.5B as of 2025) employ transport vehicle (TV) technology engineered to bind endogenous receptors for BBB crossing [Denali Therapeutics]. Others, such as Ikarovec (formerly Iksuda Therapeutics), focus on antibody-drug conjugates (ADCs) with enhanced CNS delivery. These are Nanocarry's most direct conceptual competitors, as they also aim for a modular delivery system applicable to multiple biologics.
• Academic & Early-Stage Spinouts. The landscape includes numerous academic groups and nascent startups, often in Israel and Europe, exploring nanoparticle, liposome, or focused ultrasound-mediated BBB disruption. Their differentiation is typically a novel material science or engineering angle, but they generally lack the integrated therapeutic development and business infrastructure of a dedicated company like Nanocarry.

Nanocarry's defensible edge today rests on the specific engineering of its AxS platform: a gold nanoparticle core designed to "hitch a ride" with insulin receptors [Bar-Ilan University]. This mechanistic approach, supported by preclinical data showing up to 30-fold increased antibody delivery, is a tangible technical differentiator from both large pharma's molecule-by-molecule optimization and some competing platforms that target different receptor systems. The "Plug and Play" claim suggests a focus on ease of conjugation, which could lower barriers for potential pharma partners. However, this edge is highly perishable; it remains preclinical and unvalidated in human trials. Durability depends on translating animal model efficacy into clinical proof-of-concept and securing intellectual property that covers both the nanoparticle construct and its therapeutic applications broadly.

The company's most significant exposure is its stage relative to better-capitalized, clinical-stage platform companies. Denali Therapeutics, for instance, has multiple programs in clinical trials, a public company's financing access, and established partnerships with Biogen and Sanofi [Denali Therapeutics]. This represents a formidable commercial and development head start. Nanocarry also cannot easily enter the adjacent field of small-molecule CNS drug delivery, where different pharmacokinetic principles apply, limiting its total addressable market to biologic therapies unless the platform is radically adapted.

The most plausible 18-month competitive scenario hinges on validation and partnership. A winner emerges if a major pharma licensee selects one platform technology for a high-value CNS program, providing non-dilutive capital and clinical validation that could crowd out other approaches. In this case, a company like Denali, with its clinical data, would be strongly positioned to win such a deal. Conversely, a loser scenario unfolds if the preclinical efficacy of a platform fails to translate in initial human studies, a common risk in CNS drug development. If Nanocarry's lead candidate, AxS-007, does not demonstrate clear superiority over simpler methods in early trials, the company could struggle to attract further funding or partnership interest, ceding ground to competitors with more advanced pipelines or alternative technological bets.

Data Accuracy: YELLOW -- Landscape analysis is inferred from public company pipelines and scientific literature; no direct competitive intelligence from Nanocarry is available.

Opportunity

PUBLIC

The prize for Nanocarry Therapeutics is the creation of a de facto standard for delivering biologic drugs to the central nervous system, unlocking a therapeutic category that has been largely inaccessible for decades.

The headline opportunity is to become the enabling platform for a new generation of brain-penetrant biologics. The company's cited preclinical evidence positions its AxS technology not as a single drug but as a delivery system that could be licensed across multiple therapeutic areas [Bar-Ilan University]. The core claim, that the platform can be easily modified to deliver a wide array of biologics using a proprietary "Plug and Play" approach, directly supports a platform business model rather than a single-asset development path [LinkedIn]. This suggests a future where Nanocarry's primary revenue comes from licensing fees and development milestones from pharmaceutical partners seeking to retrofit their existing antibody pipelines for CNS efficacy, a role analogous to drug delivery specialists like Ablynx (acquired by Sanofi) or, more recently, bioconjugation platform companies.

Growth scenarios for the company hinge on translating its preclinical validation into strategic partnerships and clinical proof-of-concept.

Scenario	What happens	Catalyst	Why it's plausible
Platform Licensing to Big Pharma	Nanocarry signs a multi-target collaboration with a major oncology or neuroscience-focused pharmaceutical company, providing upfront cash and downstream royalties.	Selection of the AxS platform for a specific development program, as previously reported [FirstWord Pharma], evolves into a broader framework agreement.	The unmet need is acute, and large pharma routinely in-licoses enabling technologies to de-risk their internal pipelines. The "Plug and Play" claim is designed to appeal to this exact buyer.
Lead Asset Spin-out or Acquisition	The company's lead candidate for HER2+ breast cancer brain metastases (AxS-007) advances through Phase 1/2a clinical trials, demonstrating safety and a biomarker signal, leading to an acquisition by an oncology specialist.	Successful completion of a Series A round, which would fund the candidate into early human trials.	Neuro-oncology assets with novel delivery mechanisms command significant premiums. Preclinical data showing up to 30x increased delivery provides a strong rationale for a trade sale before late-stage clinical risk [Bar-Ilan University].

What compounding looks like for Nanocarry is a data-driven platform moat. Each new biologic successfully conjugated to the AxS nanoparticle and tested, whether internally or by a partner, generates proprietary data on linker chemistry, payload compatibility, and pharmacokinetics. This growing dataset would refine the "Plug and Play" system, making subsequent conjugations faster, more predictable, and more effective. Early recognition, such as the platform selection noted by FirstWord Pharma, can attract further partnership interest, creating a virtuous cycle where platform validation begets more deals, which in turn generate more validating data.

The size of the win can be framed by looking at comparable platform transactions. For instance, the 2018 acquisition of Ablynx by Sanofi for approximately €3.9 billion centered on a proprietary nanobody platform with multiple partnered programs. While Nanocarry is earlier-stage, a successful execution of the Platform Licensing scenario could see it building a portfolio of partnered programs that, in aggregate, approach such a valuation. In the Lead Asset Spin-out scenario, a more direct comparison might be the acquisition of CNS-focused biotechs with promising Phase 1/2 assets, which often occur in the $500 million to $2 billion range. It is critical to note these are illustrative scenarios based on historical precedent, not a forecast for Nanocarry.

Data Accuracy: YELLOW -- Opportunity analysis is based on cited platform claims and preclinical data; commercial traction and partnership details are not publicly available.

Sources

PUBLIC

1. [LinkedIn] Nanocarry Therapeutics | https://il.linkedin.com/company/nanocarry-therapeutics

2. [Bar-Ilan University] The Israeli Startup That’s Breaching the Brain’s Defenses | https://www.biu.ac.il/en/article/583781

3. [Tracxn] NanoCarry - 2025 Company Profile, Team & Competitors | https://tracxn.com/d/companies/nanocarry/__KzBHeN2ttmdgpEu_iYKIvMdQYDQHKGuJkuIUpsYCSwM

4. [Prospeo] Nanocarry Therapeutics - Revenue, Employees, Funding, Acquisitions | https://prospeo.io/c/nanocarry-therapeutics-revenue

5. [Synapse-Patsnap] Nanocarry Therapeutics Contact Information | https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/e23bc986063c0e3fa84c504579d6a7d6

6. [Nanocarry] About - Nanocarry | https://nanocarry.com/about/

7. [Nanocarry] Nanocarry Therapeutics Pipeline | https://nanocarry.com/pipeline/

8. [FirstWord Pharma, 2022] FirstWord Pharma News | https://firstwordpharma.com/story/5892142

9. [Grand View Research, 2023] Brain Tumor Treatment Market Size Report | https://www.grandviewresearch.com/industry-analysis/brain-tumor-treatment-market

10. [CNS Oncology, 2022] Epidemiology of brain metastases | https://www.futuremedicine.com/doi/10.2217/cns-2021-0011

11. [FDA, 2024] Breakthrough Therapy Designations | https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy

12. [Denali Therapeutics] Denali Therapeutics | https://www.denalitherapeutics.com/